• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Laronidase Product Approval Information - Licensing Action

Proper name: Laronidase
Tradename: Aldurazyme
Manufacturer: Biomarin Pharmaceutical Inc, Novato, CA, License #1649
Indication for Use:For patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. The risks and benefits of treating mildly affected patients with the Scheie form have not been established. Laronidase has been shown to improve pulmonary function and walking capacity. Laronidase has not been evaluated for effects on the central nervous system manifestations of the disorder.
Approval Date: 4/30/2003
Type of submission: Biologics license application


Label (PDF)

      Assay Review (PDF)
      CMC Product Review (PDF)
      Medical Officer Review (PDF)
      Review (PDF)
      Review (PDF)
      Review (PDF)
      Toxicologist's Review (PDF)